News
February 19, 2019
Forbes Recognizes Clinicom for its accomplishments in Mental Health!
When it comes to health and tech innovation, people have spent years talking about how Gen Z and Millennials – along with their Silicon Valley startups – are going to disrupt the health ecosystem. Those “in the know” have been fond of claiming they are going to be the next Uber or AirBnB of health. And everyone is scrambling to be at the forefront of “personalized medicine.” But the truth is, our most basic health needs and care requirements have been known for a long time.
January 01, 2020
Centers for Psychiatric Excellence (COPE) Complete Integration of Online Assessment and Tracking Software with CLINICOM™ to Help Improve Long-Term Patient Outcomes
COPE to present on this cutting-edge software integration, along with the latest research on innovative treatments, including ketamine infusion, for patients suffering from treatment-resistant psychiatric disorders at the American Psychiatric Association (APA) Annual Meeting in New York, NY, on May 7, 2018.
March 19, 2018
A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD)
Background Mazindol is under investigation for the treatment of attention-deficit/hyperactivity disorder (ADHD) because of its alertness-enhancing properties. A novel controlled-release (CR) formulation of mazindol was developed to allow once-daily dosing. Objective The aim of this study was to evaluate the effi- cacy of mazindol CR in adults with ADHD. Design We conducted a randomized, double-blind, placebo-controlled 6-week trial.